INFORMATIONAL PURPOSES ONLY. Not medical, legal, or travel advice. Verify with official sources before acting. See corrections log.
Right to try laws and requirements in Georgia. Citations, verification dates, and source links for every data point.
| Dimension | Value | Citation | Source | Verified | Confidence |
|---|---|---|---|---|---|
| Have Enacted State Right to Try Laws | have state RTT laws | O.C.G.A. § 31-52-1 et seq.“"Investigational drug, biological product, or device" means a drug, biological product, or device which has successfully completed Phase I of a federal Food and Drug Administration approved clinical trial” | Link | 2026-10-09 | high |
| Enacted Right to Try Laws Before Federal Law | 2016 | O.C.G.A. § 31-52-1; Ga. L. 2016, p. 345 (HB 34)“Georgia Right to Try Act." (Code 1981, § 31-52-1 , enacted by Ga. L. 2016, p. 345, § 1/HB 34.)” | Link | 2026-10-09 | high |
| Require Individualized Manufacturer Approval for RTT | require individualized approval | Ga. 2025 Act 122 (SB 72), O.C.G.A. Ch. 31-52, Art. 2“SB 72 This Act enacts the "Hope for Georgia Patients Act." The Act provides for requirements for an eligible patient to receive individualized investigational treatment”Note: SB 72 (2025), the 'Hope for Georgia Patients Act', enacted new Article 2 of O.C.G.A. Ch. 31-52 for individualized investigational treatment; effective July 1, 2025 per the official summary. Georgia was not on the brief's lead list. | Link | 2026-10-09 | high |
| Provide Manufacturer Liability Protection Under RTT | provide liability shield | O.C.G.A. § 31-52-10(a)“This chapter shall not be construed to create a private cause of action against a manufacturer of an investigational drug, biological product, or device ... if the manufacturer ... is complying in good faith”Note: 'No private cause of action' clause (not an immunity), qualified by good faith and reasonable care. § 31-52-10(b) separately bars liability of treating persons/entities absent failure to obtain informed consent. Text is from the code as enacted in 2016; SB 72 (2025) amended § 31-52-10, and the post-2025 wording was not reviewed, though the official summary says the Act 'limits the causes of action' rather than removing them. | Link | 2026-10-09 | high |
| Require Insurer Coverage of Investigational Treatments | do not require coverage | O.C.G.A. § 31-52-7“nothing in this chapter shall be construed to require a health benefit plan or governmental agency to provide coverage for the cost of any investigational drug, biological product, or device pursuant to this chapter.” | Link | 2026-10-09 | high |
View full Georgia profile (all layers) · Report an error on this page